Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation

SIMPLE SUMMARY: Anti-PD-1/PD-L1 and anti-CTLA-4-based immune checkpoint blockade (ICB) immunotherapy have recently emerged as a breakthrough in human cancer treatment. Durable efficacy has been achieved in many types of human cancers. However, not all human cancers respond to current ICB immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Moorman, Hannah R., Poschel, Dakota, Klement, John D., Lu, Chunwan, Redd, Priscilla S., Liu, Kebin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698217/
https://www.ncbi.nlm.nih.gov/pubmed/33203146
http://dx.doi.org/10.3390/cancers12113379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698217/
https://www.ncbi.nlm.nih.gov/pubmed/33203146
http://dx.doi.org/10.3390/cancers12113379

Ejemplares similares